sorafenib has been researched along with Hepatitis C in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (11.11) | 29.6817 |
| 2010's | 28 (77.78) | 24.3611 |
| 2020's | 4 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Kuwano, A; Masumoto, A; Morita, Y; Motomura, K; Nagasawa, S; Tanaka, K; Yada, M | 1 |
| Chang, CS; Lee, SW; Lee, TY; Peng, YC; Yang, SS; Yeh, HZ | 1 |
| Aleixo, MJ; Fonseca, C; Fonseca, J; Nunes, G; Patita, M; Ramalho, M | 1 |
| El-Badawy, O; Eldin, AS; Fakhry, H; Hassan, EA; Hetta, HF; Rayan, A; Soliman, A; Zahran, AM | 1 |
| Berhane, S; Hoare, M; Janowitz, T; Johnson, P; Kolamunnage-Dona, R; Potts, H; Tanner, J; Williams, EH | 1 |
| Casadei Gardini, A; Ercolani, G; Foschi, FG; Frassineti, GL; Ulivi, P | 1 |
| Cheng, SB; Huang, CC; Jan, YG; Lin, HC; Lin, YL; P'eng, FK; Shen, CH; Teng, CJ; Wu, CC; Yang, YS | 1 |
| Ahmed, B; Ghaffar, A; Jalal, F; Kamran, SK; Kiran, S; Munir, B; Oranab, S; Shehzadi, S; Zahoor, MK | 1 |
| Chu, PS; Ebinuma, H; Fukasawa, M; Ikeda, M; Kanai, T; Kato, N; Koda, Y; Murakami, Y; Nakamoto, N; Ojiro, K; Saito, H; Saito, K; Saito, Y; Sugiyama, K; Suzuki, T; Taniki, N; Teratani, T | 1 |
| Dong, W; Guo, XG; He, XD; Liu, FC; Liu, H; Wang, ZH | 1 |
| Amanuma, M; Daido, Y; Higai, K; Igarashi, Y; Kobayashi, K; Matsui, D; Matsui, T; Matsukiyo, Y; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Shinohara, M; Wakui, N; Yoshimine, N | 1 |
| Anderson, J; Chao, Y; Choo, SP; Chopra, A; Cruz, CD; Hou, MM; Hsu, C; Ikeda, M; Kang, YK; Kim, TY; Kudo, M; Kuromatsu, R; Moriguchi, M; Numata, K; Yau, T; Yeo, W; Zhao, H | 1 |
| D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P | 1 |
| Akiba, J; Kusano, H; Nakayama, M; Ogasawara, S; Ueda, K; Yano, H | 1 |
| Abecassis, M; Al-Saden, P; Baker, T; Cotliar, J; Ganger, D; Habib, A; Karp, J; Koppe, S; Kulik, L; Lacouture, M; Lewandowski, RJ; Mulcahy, MF; Salem, R; Vouche, M | 1 |
| Anand, BS; Fitzmorris, P; Shoreibah, M; Singal, AK | 1 |
| Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N | 1 |
| Chan, SY; Cheng, AL; Hsu, CH; Lu, LC; Shao, YY; Shau, WY | 1 |
| Bose, SK; Di Bisceglie, AM; Kwon, YC; Meyer, K; Ray, R; Ray, RB; Steele, R | 1 |
| Bhatia, S; Dinh, VY; Feun, L; Martin, P; Narayanan, G; O'Brien, C; Savaraj, N; Yrizarry, J | 1 |
| Pár, A; Pár, G | 1 |
| Choi, JI; Kim, CM; Park, BJ; Park, JW; Shim, JH | 1 |
| Bellot, P; Llanos, L; Pérez-Mateo, M; Such, J; Zapater, P | 1 |
| Mendizabal, M; Reddy, KR | 1 |
| Bruera, G; Giordano, AV; Lapecorella, M; Lucchesi, A; Mariani, G; Napolitano, M; Ricevuto, E; Tudini, M | 1 |
| Aitini, E; Cengarle, R; Costa, P; Fibbia, GC; Morandini, B; Perboni, G; Scalzini, A; Tagliani, A | 1 |
| Bhoori, S; Germini, A; Lampis, A; Mazzaferro, V; Pellegrinelli, A; Sposito, C; Toffanin, S | 1 |
| Finn, RS | 1 |
| Fischer, L; Herden, U; Nashan, B; Schäfer, H; Sterneck, M; von Baehr, V | 1 |
| Bruix, J; Sherman, M | 1 |
| Ballarin, R; Berretta, M; D'Amico, G; De Ruvo, N; Di Benedetto, F; Gerunda, GE; Iemmolo, RM; Tarantino, G | 1 |
| Kudo, M | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, EH; Kim, SU; Lee, DY; Park, JY; Park, MS; Seong, J | 1 |
| Friedman, SL | 1 |
| Dogan, E; Koca, D; Olmez, A; Yalcin, S | 1 |
| Cabrera, R; Clark, V; Firpi, R; Horne, P; Limaye, AR; Mills, R; Morelli, G; Nelson, DR; Soldevila-Pico, C | 1 |
4 review(s) available for sorafenib and Hepatitis C
| Article | Year |
|---|---|
Management of hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Management; Hepatitis B; Hepatitis C; Hepatitis, Viral, Human; Humans; Incidence; Liver Neoplasms; Mass Screening; Niacinamide; Palliative Care; Phenylurea Compounds; Population Surveillance; Quality of Life; Sorafenib; Viral Hepatitis Vaccines | 2015 |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Current management of hepatocellular carcinoma.
Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease Progression; Hepatectomy; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Liver Transplantation; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Trials as Topic; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Meta-Analysis as Topic; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Pyridines; Recombinant Proteins; Ribavirin; Sorafenib | 2011 |
3 trial(s) available for sorafenib and Hepatitis C
| Article | Year |
|---|---|
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Asia; B7-H1 Antigen; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Nivolumab; Sorafenib; Treatment Outcome; Young Adult | 2019 |
Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Graft Rejection; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Radiation Dosage; Sorafenib; Yttrium Radioisotopes | 2014 |
Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Cisplatin; Female; Hepatic Artery; Hepatitis C; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Sorafenib | 2016 |
29 other study(ies) available for sorafenib and Hepatitis C
| Article | Year |
|---|---|
Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Prognosis; Retrospective Studies; Sorafenib | 2022 |
Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis | 2019 |
Diffuse advanced hepatocellular carcinoma after HCV eradication in an HIV-infected patient: A unique complete response to sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Coinfection; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Induction Chemotherapy; Liver Neoplasms; Male; Sorafenib | 2020 |
Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Capecitabine; Carcinoma, Hepatocellular; Case-Control Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis A Virus Cellular Receptor 2; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Programmed Cell Death 1 Receptor; Receptors, CCR5; Sorafenib; Survival Rate; T-Lymphocytes | 2020 |
Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Growth and Development; Hepatitis C; Humans; Liver; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Sorafenib | 2021 |
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials.
Topics: Carcinoma, Hepatocellular; Double-Blind Method; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2017 |
Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Hematologic Neoplasms; Hepacivirus; Hepatectomy; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Patient Selection; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Serologic Tests; Sorafenib; Survival Rate; Young Adult | 2017 |
Sorafenib tosylate, Ribavirn and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Ribavirin; Sofosbuvir; Sorafenib; Sustained Virologic Response; Treatment Outcome | 2017 |
Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells.
Topics: Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Hepatitis C; Humans; Liver Neoplasms; NF-E2-Related Factor 2; Quassins; RNA, Viral; Sorafenib; Transcriptome; Virus Replication | 2018 |
Specific CYP450 Genotypes in the Chinese Population Affect Sorafenib Toxicity in HBV/HCV-associated Hepatocellular Carcinoma Patients.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Genotype; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Rats, Sprague-Dawley; Sorafenib; Young Adult | 2018 |
Influence of Sorafenib on Host Immunity in Patients with Liver Cirrhosis With Advanced Hepatocellular Carcinoma Stratified by Etiology.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Hepatitis C; Humans; Interferon-gamma; Interleukin-4; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Sorafenib; Th2 Cells | 2019 |
Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Dose-Response Relationship, Drug; Fibrosis; Hepatitis B; Hepatitis C; Humans; Hypertension; Italy; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Weight Loss | 2013 |
Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Sorafenib | 2013 |
Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatic Artery; Hepatitis C; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Reproducibility of Results; Retrospective Studies; Risk Factors; Sorafenib; Treatment Failure | 2014 |
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cyclic S-Oxides; Dasatinib; Epithelial-Mesenchymal Transition; Female; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imatinib Mesylate; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; RNA, Messenger; Sorafenib; Spheroids, Cellular; STAT3 Transcription Factor; Transplantation, Heterologous; Tumor Cells, Cultured | 2015 |
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008].
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Delayed-Action Preparations; Europe; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Neoplasms; Niacinamide; Oligopeptides; Patient Compliance; Phenylurea Compounds; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Societies, Medical; Sorafenib | 2008 |
Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B; Hepatitis C; Humans; Korea; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2009 |
Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Factor VIII; Hemophilia A; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib | 2010 |
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; beta Catenin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; DNA Mutational Analysis; Everolimus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Point Mutation; Precision Medicine; Pyridines; Ribavirin; Sirolimus; Sorafenib | 2010 |
Drug therapy: sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Factors; Sorafenib | 2010 |
Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis C; Hepatitis, Autoimmune; Humans; Liver Neoplasms; Mass Screening; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Ultrasonography | 2011 |
Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome | 2012 |
Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Child; Female; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Republic of Korea; ROC Curve; Sorafenib; Treatment Outcome; Young Adult | 2012 |
Focus.
Topics: Animals; Cell Transformation, Neoplastic; Epithelial-Mesenchymal Transition; Hepatic Veno-Occlusive Disease; Hepatitis C; Hepatocytes; Humans; Male; MAP Kinase Kinase 4; Matrix Metalloproteinase 9; Monocrotaline; Niacinamide; Phenylurea Compounds; Sorafenib; Viral Nonstructural Proteins | 2012 |
Clinicopathological characteristics of hepatocellular carcinoma in Turkey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; alpha-Fetoproteins; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Risk Factors; Sorafenib; Turkey; Young Adult | 2012 |
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Viral Load | 2013 |